| Literature DB >> 28540081 |
Bing Zhang1, Jie Kang1, Xiaoming Chen1.
Abstract
Purpose. This system review studied the efficiency and safety of canaloplasty (CP) and compared the outcomes between CP and trabeculectomy (TE). Methods. Literatures were searched in PubMed and EMBASE. The meta-analysis was conducted on the postoperative outcomes in CP and then on the differences of outcomes between CP and TE. Results. In the meta-analysis, IOP decreased by 9.94 (95% CI 8.42 to 11.45) mmHg with an average AGM reduction of 2.11 (95% CI 1.80 to 2.42) one year after CP. The IOP reduction was significantly higher after TE than after CP, with an average difference of 3.61 (95% CI 1.69 to 5.53) mmHg at 12 months postoperationally. For complications, the incidence of hyphema was significantly higher in CP and the Descemet membrane detachment was just reported in CP, with an incidence of 3%. However, the incidence was significantly lower in CP of hypotony and of choroidal effusion/detachment. Meanwhile, suprachoroidal hemorrhage and bleb needling were only reported in TE. Conclusions. CP was less effective in IOP reduction than TE, but CP was able to achieve similar postoperative success rates and reduce the number of AGMs likewise. CP was also associated with lower incidence of complications. More high-quality researches are needed in the future to verify our findings in this system review.Entities:
Year: 2017 PMID: 28540081 PMCID: PMC5429958 DOI: 10.1155/2017/2723761
Source DB: PubMed Journal: J Ophthalmol ISSN: 2090-004X Impact factor: 1.909
Figure 1Flow diagram for study selection.
Characteristics and baseline information of included literatures.
| Study type | Age, mean (SD) | Male% | Eyes at baseline | POAG% | Baseline IOP, | Baseline AGMs, | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Ayyala et al. [ | Retrospective | 68.3 (10.0) | 52 | 33 | NA | 21.2 (6.6) | 2.5 (0.8) |
| Barnebey [ | Retrospective | 68.2 (13.1) | 55 | 20 | 100 | 23.4 (4.3) | 2.2 (1.2) |
| Brandao et al. [ | Prospective | 71.3 (7.3) | 41 | 19 | 74 | 24.6 (5.3) | 2.5 (0.8) |
| Bruggemann and Muller [ | Retrospective | 62.7 (NA) | 52 | 21 | 100 | 28.8 (9.6) | 2.9 (1.0) |
| Brusini [ | Prospective | 63.5 (14.0) | NA | 214 | 74 | 29.4 (7.9) | 3.3 (0.9) |
| Gandolfi et al. [ | Retrospective | NA | 67 | 24 | 67 | 26.0 (4.0) | 2.7 (3.3) |
| Grieshaber et al. [ | Prospective | 49.8 (15.7) | 43 | 60 | 100 | 45.0 (12.1) | NA |
| Grieshaber et al. [ | Prospective | 70.8 (8.4) | 49 | 47 | 100 | 26.8 (5.2) | 2.8 (0.5) |
| Grieshaber et al. [ | Prospective | 71.8 (8.8) | 41 | 22 | 100 | 27.1 (5.3) | 2.9 (0.6) |
| Kalin-Hajdu et al. [ | Retrospective | 40.0 (19.2) | NA | 19 | 0 | 30.4 (8.4) | 3.7 (0.8) |
| Lewis et al. [ | Prospective | 67.6 (11.6) | 47 | 103 | 89 | 23.5 (4.5) | 1.9 (0.8) |
| Lommatzsch et al. [ | Retrospective | 40.7 (21.8) | 25 | 14 | 0 | 27.1 (12.3) | 2.7 (1.1) |
| Lopes-Cardoso et al. [ | Prospective | 73.4 (6.0) | 66 | 11 | 37 | 24.5 (5.1) | 3.4 (0.5) |
| Matlach et al. [ | RCT | 66.5 (11.3) | 60 | 30 | 43 | 23.7 (5.1) | 2.6 (1.6) |
| Matthaei et al. [ | Retrospective | 65.2 (12.4) | 46 | 33 | 87 | 18.5 (6.3) | 2.3 (1.2) |
| Moelle et al. [ | Retrospective | 62 (9) | 42 | 26 | 54 | 21.1 (5.8) | 2.5 (1.8) |
| Seuthe et al. [ | Retrospective | 66.7 (11.4) | NA | 417 | 86 | 20.9 (3.5) | 3.5 (0.9) |
| Thederan et al. [ | Retrospective | 72.9 (5.2) | 64 | 22 | 68 | 23.7 (7.6) | 3.1 (1.2) |
| Voykov et al. [ | Retrospective | 60 (11) | 45 | 20 | 75 | 25.7 (6.6) | 3.4 (0.5) |
| Wang et al. [ | Retrospective | 39.1 (13.8) | 77 | 17 | NA | 24.7 (8.7) | 2.4 (1.7) |
| Xin et al. [ | Prospective | 38 (12.8) | 65 | 17 | 100 | 29.9 (8.2) | 2.9 (0.9) |
|
| |||||||
| Arthur et al. [ | Retrospective | 76.1 (8.3) | 56 | 32 | 84 | 18.2 (5.1) | 1.3 (0.7) |
| Lewis et al. [ | Prospective | 67.6 (11.6) | 47 | 30 | 89 | 23.5 (5.2) | 1.5 (1.0) |
| Lopes-Cardoso et al. [ | Prospective | 73.4 (6.0) | 66 | 24 | 37 | 19.8 (6.8) | 3.3 (0.5) |
| Matlach et al. [ | Retrospective | 72.9 (5.7) | 47 | 19 | 47 | 28.3 (4.1) | 2.8 (1.1) |
| Matthaei et al. [ | Retrospective | 65.2 (12.4) | 46 | 13 | 87 | 17.5 (4.2) | 2.5 (1.3) |
| Rekas et al. [ | RCT | 74.6 (8.9) | 59 | 29 | 83 | 19.0 (6.9) | 2.6 (0.7) |
| Schoenberg et al. [ | Retrospective | 66.8 (8.5) | 67 | 36 | 94 | 19.5 (5.7) | NA |
|
| |||||||
| Alobeidan and Almobarak [ | Retrospective | 53.4 (15.0) | 60 | 105 | 67 | 19.0 (6.7) | 2.6 (1.3) |
| Fujita et al. [ | Retrospective | 71.7 (8.5) | NA | 11 | 100 | 23.4 (5.5) | 2.8 (0.6) |
| Rekas et al. [ | Prospective | 69.3 (11.4) | 40 | 10 | 90 | 19.1 (3.4) | 2.2 (1.1) |
AGM: antiglaucoma medication; CP: independent canaloplasty subgroup in corresponding literature; NA: data not available; PCP: phacocanaloplasty subgroup in corresponding literature; POAG: primary open-angle glaucoma; RCT: randomized controlled trials.
Meta-analysis outcomes of reductions in IOP and antiglaucoma medications (AGMs) at 6 and 12 months postoperationally.
| IOP reduction (95% CI) mmHg | AGMs, reduction (95% CI) | ||
|---|---|---|---|
| Standalone canaloplasty | 6 months | 12.01 (9.77, 14.24) | 2.01 (1.51, 2.50) |
| 12 months | 11.38 (9.43, 13.34) | 2.16 (1.79, 2.53) | |
| Phacocanaloplasty | 6 months | 8.32 (5.36, 11.27) | 2.03 (1.36, 2.70) |
| 12 months | 8.14 (4.83, 11.46) | 2.04 (1.15, 2.92) |
Incidence of complications of canaloplasty.
| Complications | Incidence% (events/pooled eyes) |
|---|---|
| Hyphema (blood layer > 1 mm) | 24.9 (304/1221) |
| Hypotony < 5 mmHg | 8.6 (94/1091) |
| Descemet membrane detachment | 3.1 (37/1185) |
| Detectable conjunctival bleb | 1.9 (17/899) |
Figure 2Comparison of the reductions in IOP and antiglaucoma medications (AGMs) between canaloplasty (CP) and trabeculectomy (TE) (PCP = phacocanaloplasty, PTE = phacotrabeculectomy).
Figure 3Comparison of success rates between canaloplasty (CP) and trabeculectomy (TE) (independent CP versus TE in Matlach et al. [22] and Thederan et al. [26]; PCP versus PTE in Matlach [31]; PCP = phacocanaloplasty, PTE = phacotrabeculectomy).
Figure 4Comparison of complications between canaloplasty (CP) and trabeculectomy (TE).